Skip to main content
Top

Open Access 25-04-2024 | Epigenetics | Special supplement: MAFLD

The contribution of genetics and epigenetics to MAFLD susceptibility

Authors: Vittoria Moretti, Stefano Romeo, Luca Valenti

Published in: Hepatology International

Login to get access

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease worldwide. The risk of developing MAFLD varies among individuals, due to a combination of environmental inherited and acquired genetic factors. Genome-wide association and next-generation sequencing studies are leading to the discovery of the common and rare genetic determinants of MAFLD. Thanks to the great advances in genomic technologies and bioinformatics analysis, genetic and epigenetic factors involved in the disease can be used to develop genetic risk scores specific for liver-related complications, which can improve risk stratification. Genetic and epigenetic factors lead to the identification of specific sub-phenotypes of MAFLD, and predict the individual response to a pharmacological therapy. Moreover, the variant transcripts and protein themselves represent new therapeutic targets. This review will discuss the current status of research into genetic as well as epigenetic modifiers of MAFLD development and progression.
Literature
20.
go back to reference Romeo S, Valenti L. African genetic ancestry and protection against fatty liver disease. Liver Int 2022;42:2122–2123CrossRefPubMed Romeo S, Valenti L. African genetic ancestry and protection against fatty liver disease. Liver Int 2022;42:2122–2123CrossRefPubMed
21.
go back to reference Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268–279CrossRefPubMed Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268–279CrossRefPubMed
36.
go back to reference Sveinbjornsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet 2022;54(11):652–1663CrossRef Sveinbjornsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet 2022;54(11):652–1663CrossRef
42.
go back to reference Burnett JR, Hooper AJ, Hegele RA. APOB-related familial hypobetalipoproteinemia. GeneReviews® [Internet] 2021;1993–2023 Burnett JR, Hooper AJ, Hegele RA. APOB-related familial hypobetalipoproteinemia. GeneReviews® [Internet] 2021;1993–2023
54.
go back to reference Eslam M, Ahlenstiel G, George J. Interferon lambda and liver fibrosis. J Interf Cytokine Res 2019;39(10):627–635CrossRef Eslam M, Ahlenstiel G, George J. Interferon lambda and liver fibrosis. J Interf Cytokine Res 2019;39(10):627–635CrossRef
55.
go back to reference Kitamoto A, et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 2014;64(7):683–689CrossRef Kitamoto A, et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 2014;64(7):683–689CrossRef
56.
go back to reference Dongiovanni P, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010;59(2):267–273CrossRefPubMed Dongiovanni P, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010;59(2):267–273CrossRefPubMed
98.
go back to reference Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). Microrna 2018;7(3):215–222CrossRefPubMed Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S. Serum miR-29a and miR-122 as potential biomarkers for non-alcoholic fatty liver disease (NAFLD). Microrna 2018;7(3):215–222CrossRefPubMed
Metadata
Title
The contribution of genetics and epigenetics to MAFLD susceptibility
Authors
Vittoria Moretti
Stefano Romeo
Luca Valenti
Publication date
25-04-2024
Publisher
Springer India
Published in
Hepatology International
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-024-10667-5
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare